Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Dysregulation of the c-Met signaling pathway, driven by MET gene amplification, overexpression of c-Met/HGF, or kinase domain mutations, is implicated in cancer progression.
• Activated c-Met signaling promotes tumor cell proliferation, survival, invasion, and metastasis, making it a critical therapeutic target.

Purpose of the Study:

• To discover and develop novel small molecule inhibitors targeting the c-Met signaling pathway.
• To optimize lead compounds for potency, selectivity, and pharmacokinetic properties for potential cancer treatment.

Main Methods:

• Structure-based drug design and structure-activity relationship (SAR) studies were employed to optimize the 8-fluorotriazolopyridine scaffold.
• Metabolite identification was performed to assess drug metabolism and pharmacokinetics.
• In vitro cellular assays determined inhibitory potency (IC50), and in vivo studies evaluated pharmacodynamic effects in a mouse liver model.

Main Results:

• Discovery of 8-fluorotriazolopyridines as potent inhibitors of c-Met activity.
• Optimization yielded compounds with cellular IC50 values below 10 nM.
• Inhibitors demonstrated desirable pharmacokinetic properties and potent inhibition of HGF-mediated c-Met phosphorylation in vivo.

Conclusions:

• 8-Fluorotriazolopyridines represent a promising class of c-Met inhibitors.
• These compounds exhibit potent and selective inhibition with favorable drug-like properties.
• The developed inhibitors show potential for therapeutic intervention in cancers driven by c-Met signaling.